Obama Signals Interest In Reducing The Protections For Biologic Drugs

Lobbyists for generic biologic drugmakers are fighting to undercut a provision in the proposed health overhaul that would protect brand-name pharmaceutical companies from lower-cost, generic competition over new products for 12 years, the Associated Press reports. The generic companies have friends in high places: “White House officials and Rep. Henry Waxman, D-Calif…

More: continued here

Filed under: Medicare / Medicaid / Tricare on January 18th, 2010